Literature DB >> 31388594

DFT and molecular docking investigations of oxicam derivatives.

Y Shyma Mary1, Y Sheena Mary1, K S Resmi1, Renjith Thomas2.   

Abstract

The organic molecule n class="Chemical">tenoxicam and similar derivatives, class="Chemical">pan class="Chemical">piroxicam and isoxicam have been studied by quantum chemical theory (DFT), FT-Raman and FT-IR. By FMOs energies the charge transfer inside the molecules are obtained. The UV-Vis spectra of the compounds are simulated to study the electronic transition in the target molecules. By using natural bond orbital (NBO), charge delocalization analyzes arising from hyper conjugative interactions and the stability of the molecules are obtained. First order hyperpolarizability of piroxicam is higher than that of isoxicam and tenoxicam. The reactive areas are thoroughly studied by MEP. Prediction of Activity Spectra gives activities, anti-inflammatory, CYP2C9 substrate and gout treatment. Docked ligands form a stable complex with the receptors.

Entities:  

Keywords:  DFT; FT-IR; FT-Raman; MEP; Molecular docking; Organic chemistry; Pharmaceutical chemistry; Theoretical chemistry

Year:  2019        PMID: 31388594      PMCID: PMC6667822          DOI: 10.1016/j.heliyon.2019.e02175

Source DB:  PubMed          Journal:  Heliyon        ISSN: 2405-8440


Introduction

n class="Chemical">Oxicams are class="Chemical">pan class="Chemical">enolcarboxamides that exhibit number of pharmacological properties and effective for postoperative pain, arthritis, degenerative joint diseases and osteoarthritis [1]. Tenoxicam is a nonsteroidal anti-inflammatory drug that is a part of the oxicam family and it can be used as an effective analgesic and antipyretic agent [2]. Piroxicam possess multifunctional activity including chemoprevention and its photochemical properties are sensitive to medium [3, 4]. Tamasi et al. [5] reported the synthesis and DFT studies of oxicam complexes. By giving the mol files of tenoxicam, piroxicam and isoxicam in the software it predicts different biological activities. Literature survey shows that there is no detailed study done on the molecules both quantum chemical and experimental spectroscopic studies which are very essential for micro level function of any organic compounds. The structural and physio-chemical properties of the compounds can be found out by spectroscopic and quantum computational tools like Density Functional Theory. These structural and physio-chemical properties can be used to establish relationships between these properties and biological activity of the compound [6]. Due to a large number of applications of NLO materials in optoelectronic technology, the molecules have been analyzed for their hyperpolarizability [7]. Several properties like highest occupied molecular orbital, lowest unoccupied molecular orbital energies, various chemical descriptors, molecular electrostatic potential analysis are carried out to provide information about charge transfer within the molecules. The spectral analysis of tenoxicam, piroxicam and isoxicam are performed and compared with theoretical values. The redistribution of electron density are investigated.

Calculation

All calculations are performed using the Gaussian09 software package [8]. DFT method was employed using B3LYP functional and cc-pVDZ (5D, 7F) basis set. Results from frequency calculations after scaling were used to get the IR spectral data, which is compared with the experimental spectral vibrations [9]. By using the TD-DFT method the electronic properties of the molecules (Fig. 1) determined using CAM-B3LYP functional and cc-pVDZ basis set. The spectral data are obtained from Bio-Rad Laboratories, Inc. SpectraBase [10].
Fig. 1

Optimized geometry of (a) tenoxicam, (b) piroxicam and (c) isoxicam.

Optimized geometry of (a) n class="Chemical">tenoxicam, (b) class="Chemical">pan class="Chemical">piroxicam and (c) isoxicam.

Results and discussions

Natural bond orbital analysis

NBO analysis provides information about various hyper conjugative interactions and intermolecular charge transfer between bonding and antibonding orbitals. In the current work the analysis has been done using DFT method at B3LYP/cc-pVDZ (5D, 7F) level. The stabilization energy forms an important characteristic in this analysis and higher this energy, greater will be the interaction between the electron pan class="Species">donors and hence greater the extent of conjugation. Intra molecular interactions are very much important in predicting the stability and reactivity of the target molecules [11]. To study intra and inter-molecular non-bonded interactions the NBO is the efficient method for organic and bio-molecular compounds [12]. Based on the second order perturbation theory the important class="Chemical">pan class="Species">donor-acceptor interactions are calculated. The important interactions are: For tenoxicam: The strong interactions are N8→π*(O6-C16), N8→π*(C18-C19), O6→ σ*(N8-C16), O5→π*(C11-C13), O4→ σ*(S1-C10), O4→ σ*(S1-O3), O3→ σ*(S1-C10), O3→ σ*(S1-O4), S2→π*(C14-C17), S2→π*(C10-C12), C18-C19→π*(C20-C22), C18-C19→π*(N9-C21), C11-C13→π*(O6-C16) with energies 79.05, 38.52, 21.56, 48.55, 22.48, 16.29,20.19, 17.93, 21.35, 26.13, 22.73, 17.71, 26.08 kcal/mol. For piroxicam: N7→π*(O5-C16), N7→π*(C19-C20), O5→ σ*(N7-C16), O4→π*(C11-C12), O3→ σ*(S1-N6), O3→ σ*(S1-C9), O2→σ*(S1-N6), O2→ σ*(S1-C9), C19-C20→π*(N8-C22), C19-C20→π*(C21-C23), C11-C12→π*(O5-C16) with energies, 79.26, 38.71, 21.48, 48.24, 34.03, 19.38, 33.32, 22.57, 17.71, 22.81, 25.94 kcal/mol and for isoxicam: N8→π*(O5-C17), N8→π*(N9-C20), O6→π*(N9-C20), O6→π*(C21-C22), O5→ σ*(N8-C17), O4→π*(C12-C13), O3→ σ*(S1-N7), O2→ σ*(S1-N7), O2→ σ*(S1-O3), O2→ σ*(S1-C10), C21-C22→π*(N9-C20), C12-C13→π*(O5-C17), C10-C14→π*(C11-C16) with energies, 74.85, 46.86, 16.12, 35.11, 22.01, 48.41, 33.52, 34.25, 18.74, 19.44, 28.36, 26.52, 19.66 kcal/mol. The delocalization energies are very high and hence the molecules are stable enough to show desired medicinal properties.

Electronic spectra and NLO properties

The 3D diagrams of HOMO and LUMO are shown in Fig. 2. HOMO represents the donating nature of an electron and LUMO represent accepting nature of electrons [13]. HOMO and LUMO energy are -7.837, -4.931 for pan class="Chemical">tenoxicam, -8.004, -5.315 for class="Chemical">pan class="Chemical">piroxicam and -7.867, -5.268 for isoxicam. The band gap energy is 2.908 for tenoxicam, 2.689 for piroxicam and 2.599 for isoxicam explains the ultimate transfer of charge happening within the molecule and shows the biological activity. The values of chemical descriptors are given in Table 1. Due to the low value of HOMO-LUMO energy gap [14] these compounds have high softness nature. The low value of the electrophilicity index suggests the biological activity of the compounds. Nonlinear optical studies are an important part in the present world of researchers as NLO active materials find applications in telecommunication, potential applications in modern communication technology, optical signal processing and data storage [15]. Molecular based nonlinear optical behavior (NLO) materials have current attention and great importance because they involve new technical phenomena owing to the emerging application in electronic devices [16]. First order hyperpolarizability of piroxicam (9.232×10−30 esu) > isoxicam (9.112×10−30 esu) > tenoxicam (7.756×10−30 esu) which are 71, 70 and 60 times that of urea while the second order values are -18.132×10−37, -18.336×10−37 and -19.060×10−37 for tenoxicam, piroxicam and isoxicam [17]. These values show that the title compounds are an important class of compounds in the rank of NLO materials [18]. Electronic transitions in a molecule usually happen in the UV and Visible region of the electromagnetic spectra. Being a time dependent phenomena, original DFT treatment could not explain this phenomenon which involves a change in the electric field of the radiations. For that time dependent density functional theory, known as TDDFT is used to simulate the electronic spectra of the compounds. Long range corrected density functional- CAM-B3LYP is used in this study with the generic 6-31G(d) basis set in methanol solvent cage as provided in the PCM solvation model [19]. In the case of tenoxicam, the DOS spectra show no unusual overlap in the frontier molecular orbitals. Simulated UV spectrum shows two strong excitations at 336.76 nm and 263.69 nm with oscillator strength 0.7602 and 0.103 respectively. The former may be due to the pi to antibonding pi orbital transitions and it is found that HOMO to LUMO transition contributes 75% to it followed by HOMOI-1 to LUMO (21%). The second transition can be attributed to the lone pair to antibonding orbital interactions, hence of low intensity. Data shows that this transition is due to HOMO-LUMO (14%), HOMO-1 to LUMO (60%) and HOMO-3 to LUMO (11%). For the compound pyroxicam, the one dominant transition was at 310 nm with oscillator strength 0.8658 due to the HOMO-1 to LUMO (21%) and HOMO to LUMO (74%), which is due to the pi to pi antibonding transition. There are other two less intense transitions too at 265.48 and 253.00 nm originating from the antibonding orbitals. Isoxicam shows an intense peak at 304.81 nm with intensity 0.6978 and can be attributed to HOMO to LUMO (91%) and HOMO-1 to LUMO (4%). There is another low intense transition originating from the lone pairs at 262.10 nm with oscillator strength of 0.0262.
Fig. 2

HOMO-LUMO plots of (a) tenoxicam, (b) piroxicam and (c) isoxicam.

Table 1

Chemical descriptors.

CompoundHOMOLUMOI = -EHOMOA = -ELUMOGapη=(I-A)/2μ = -(I + A)/2ω = μ2/2η
Tenoxicam-7.837-4.9317.8374.9312.9081.454-6.38414.015
Piroxicam-8.004-5.3158.0045.3152.6891.345-6.66016.489
Isoxicam-7.867-5.2687.8675.2682.5991.300-6.56816.592
HOMO-LUMO plots of (a) n class="Chemical">tenoxicam, (b) class="Chemical">pan class="Chemical">piroxicam and (c) isoxicam. Chemical descriptors.

Molecular electrostatic potential

pan class="Gene">MEPs map of the title compounds are shown in Fig. 3 [20]. The various surfaces of the molecule are having different electrostatic potentials and are in different colors. The negative spots are represented by red, blue is the regions of the positive and the green gives zero potential. From the diagram we can see that the negative portions are near the class="Chemical">pan class="Chemical">oxygen atoms and the N atom in the ring for all the compounds. The positive areas are around the NH groups. In this molecule, the negative regions attract proton from the amino acids or protein. These active sites are evidence of the biological activity of the title molecules.
Fig. 3

MEP plots of (a) tenoxicam, (b) piroxicam and (c) isoxicam.

n class="Gene">MEP plots of (a) class="Chemical">pan class="Chemical">tenoxicam, (b) piroxicam and (c) isoxicam.

IR and Raman spectra

Bands (Table 2) at 3390 (IR), 3411 (DFT) for n class="Chemical">tenoxicam, 3400 (IR), 3409 (DFT) for class="Chemical">pan class="Chemical">piroxicam and 3290 (IR), 3300 (Raman), 3417 (DFT) for isoxicam are assigned as the NH stretching modes [21]. The υC=O is assigned at 1610 (IR), 1605 (Raman), 1614 (DFT) for tenoxicam, 1640 (IR), 1615 (Raman), 1617 (DFT) for piroxicam and 1630 (IR), 1624 (DFT) for isoxicam [21]. The downshift of these NH and C=O modes are due to strong hyper conjugative interactions as given by NBO analysis. The C=C stretching modes are assigned at 1422 (IR), 1500, 1429 (Raman), 1501, 1422 (DFT) for tenoxicam, 1600 (IR), 1600 (Raman), 1598 (DFT) for piroxicam and at 1608, 1600 (IR), 1603 (Raman), 1606, 1590 (DFT) for isoxicam [21]. The SO2 stretching modes are assigned nearly at around 1251 (IR) and 1250 (DFT) for all the three molecules [21]. The CS stretching mode are observed at 785, 653 (tenoxicam), 631 (piroxicam), 632 (isoxicam) in IR, 668, 645 (tenoxicam), 640 (piroxicam and isoxicam) in Raman spectrum [21]. All the experimentally observed bands are identified as assigned.
Table 2

Vibrational assignments.

2.1: Tenoxicam
B3LYP/CC-pVDZ (5D, 7F)
IR
Raman
Assignmentsa
υ(cm−1)IRIRAυ(cm−1)υ(cm−1)-
341161.99188.93390-υNH
31324.1949.9031453140υCH
31093.5382.6131053110υCH
308416.36311.830883085υCH
299013.9162.943000-υCH3
290231.6273.6129152920υCH3
1614137.2371.616101605υC=O
1566142.5303.61563-υRingI
1501105.71950.4-1500υC=CRingII
1499368.034.431495-δNH
142218.88562.414221424υC=CRingIII
14062.9912.86-1404δCH3
13812.03241.3-1380δOH
13646.11127.21370-δCH3
1344152.0627.713451347υRingIII
131578.3180.181320-δCH
129292.8974.8012961290υRingI
1253176.25.311251-υSO2
124727.41126.2-1249υCN
120158.53299.012001200υCN
118679.13141.0-1188υCN
118679.13141.0-1188υCN
114131.7518.5611481147δCH
113026.3147.271138-δCH3
11029.2572.3511001100υCC
10827.355.651085-δCH3
104615.5448.9810481050δCH
100939.543.089951005υCN
9780.280.56976-γCH
90583.510.71903-γOH
89514.222.80-893δC=O
8706.9327.68-871γCH
8652.012.35858-γCH
83910.6411.24840840υRingI
78119.914.33785-υCS
76938.510.77-770τRingI
76316.9614.04760755υSN
73540.398.93737-τRingI
70338.572.00703700γNH
66211.206.26-668υCS
6567.0918.92653645υCS
58879.057.45590580δRingI
53116.053.06535536δSO2
51335.126.20-508δSO2
48017.161.48478478τRingII
4553.031.97448452τRingIII
4062.370.78403404τRingI
3052.5111.22-303τRingIII
2461.650.96-250δRingIII
1712.902.94-173τCH3

υ-stretching; δ-in-plane deformation; γ-out-of-plane deformation; τ-torsion;; IRI-IR intensity(KM/Mole); RA-Raman activity(Ǻ4/amu); RingI-pyridine ring; RingII-Ring having SO2; RingIII-Five member ring.

υ-stretching; δ-in-plane deformation; γ-out-of-plane deformation; τ-torsion;; IRI-IR intensity(KM/Mole); RA-Raman activity(Ǻ4/amu); RingI-pyridine ring; RingII-Ring having SO2; RingIII-Phenyl ring.

υ-stretching; δ-in-plane deformation; γ-out-of-plane deformation; τ-torsion;; IRI-IR intensity(KM/Mole); RA-Raman activity(Ǻ4/amu); RingI- Five member ring; RingII-Ring having SO2; RingIII-Phenyl ring.

Vibrational assignments. υ-stretching; δ-in-plane deformation; γ-out-of-plane deformation; τ-torsion;; IRI-IR intensity(KM/Mole); RA-Raman activity(Ǻ4/amu); pan class="Chemical">RingI-pyridine ring; RingII-Ring having class="Chemical">pan class="Chemical">SO2; RingIII-Five member ring. υ-stretching; δ-in-plane deformation; γ-out-of-plane deformation; τ-torsion;; IRI-IR intensity(KM/Mole); RA-Raman activity(Ǻ4/amu); pan class="Chemical">RingI-pyridine ring; RingII-Ring having class="Chemical">pan class="Chemical">SO2; RingIII-Phenyl ring. υ-stretching; δ-in-plane deformation; γ-out-of-plane deformation; τ-torsion;; IRI-IR intensity(KM/Mole); RA-Raman activity(Ǻ4/amu); RingI- Five member ring; RingII-Ring having pan class="Chemical">SO2; RingIII-Phenyl ring.

Molecular docking

PASS (Prediction of Activity Spectra) [22] gives (Table 3) activities, anti-inflammatory, pan class="Gene">CYP2C9 substrate and class="Chemical">pan class="Disease">gout treatment (activity values 0.934, 0.904 and 0.898. Receptors, 3DY9, 4NZ2 and 2AYR were obtained from the protein data bank website. PatchDock Server is used for docking purpose [23, 24, 25, 26].
Table 3

PASS prediction for the activity spectrum. Pa represents probability to be active and Pi represents probability to be inactive.

PaPiActivity
0.9340.004Antiinflammatory
0.9040.004CYP2C9 substrate
0.8980.002Gout treatment
0.8620.005Analgesic
0.8530.005Antiarthritic
0.7940.010CYP2C substrate
0.7740.004Non-steroidal antiinflammatory agent
0.7590.003Peroxidase substrate
0.7290.005Analgesic, non-opioid
0.7080.004CYP2C9 inhibitor
PASS prediction for the activity spectrum. Pa represents probability to be active and Pi represents probability to be inactive. For the protein 3DY9: the amino acid interactions are: Amino acid n class="Chemical">His129 forms H-bond with methylene while class="Chemical">pan class="Chemical">Phe13 has π-sulfur interaction with SO2 group. Lys132, Lys136 having π-alkyl interaction with pyridine ring and Trp37 shows two π-sulfur interaction with sulphur atom of the thiophene ring for tenoxicam; Lys149 forms H-bond with SO2 and Lys150, Ala275 having π-alkyl bond with pyridine ring for piroxicam and Lys149, Gly130, His129 forms H-bond with carbonyl group, SO2 group, methyl group respectively while Tys139, Lys136, Lys132 shows π-π-T shaped, alkyl, π-alkyl interaction respectively with the ligand for isoxicam. For the protein 4NZ2: The residues of n class="Chemical">Lys421 forms H-bond with methylene and OH while class="Chemical">pan class="Chemical">Asp349 shows π-anion interaction with pyridine ring. Lys420, Lys421, Lys423 having π-alkyl interaction with pyridine and phenyl ring where as Phe419 shows π-sulfur interaction with SO2 group for tenoxicam; Lys421 forms H-bond with SO2 and methyl group as well as π-alkyl interaction with pyridine ring. Lys150, Ala275 having π-alkyl interaction with phenyl ring. His353, Lys420 shows π-π-T shaped, π-alkyl interactions respectively with pyridine whereas Phe419 has a π-sulfur interaction with SO2 group for piroxicam and Amino acids Asp414, Asp349 forms π-anion interaction and Arg342 shows π-alkyl interaction with phenyl ring. Lys423, Lys421 shows π-alkyl interaction respectively with the isoxicam. For the protein 2AYR: The residues of amino acid n class="Chemical">Gly390, class="Chemical">pan class="Chemical">Trp393 forms H-bond with C=O and OH while Glu323, Glu353 shows π-anion interaction with thiophene ring and pyridine. Trp393 forms π-sulfur interaction with sulphur atom and Pro324 having π-alkyl interaction with SO2 group for tenoxicam; Amino acids Ile326, Gly390, Trp393 forms H-bond with sulphur atom, C=O, OH group respectively while Glu323, Glu353 shows π-anion interaction with pyridine. Pro324, Met357 having π-alkyl interaction with pyridine ring whereas Ile326, Lys35 gives π-sigma, π-alkyl interactions respectively with phenyl ring for piroxicam and Amino acids Glu323 forms H-bond with OH while Arg394 has π-cation interaction with phenyl ring. Leu320, Trp393 having π-alkyl with methyl and Pro324 forms π-alkyl interaction with SO2 group for isoxicam. The plot of docked ligand with receptors is shown in Fig. 4 and the docked ligand at the active site of receptors are given in Fig. 5. The docked ligands form a stable complex (Fig. 5) with these receptors with lowest ten minimum conformation of Patch Dock Energy values are tabulated in Table 4. From atomic contact energy value of pan class="Chemical">isoxicam is high in comclass="Chemical">parison with that class="Chemical">pan class="Chemical">tenoxicam and piroxicam and hence isoxicam forms more stable complex with 3DY9, 4NZ2 and 2AYR. For tenoxicam, isoxicam and piroxicam atomic contact energy is high for the protein 2AYR and has high affinity in comparison with other two proteins. The results show that the molecules have inhibitory activity against these receptors.
Fig. 4

The interactive plot of docked ligands (a) tenoxicam with 3DY9 (b) tenoxicam with 4NZ2 (c) tenoxicam with 2AYR (d) piroxicam with 3DY9 (e) piroxicam with 4NZ2 (f) piroxicam with 2AYR and (g) isoxicam with 3DY9 (h) isoxicam with 4NZ2 (i) isoxicam with 2AYR.

Fig. 5

The docked ligands (a) tenoxicam with 3DY9 (b) tenoxicam with 4NZ2 (c) tenoxicam with 2AYR (d) piroxicam with 3DY9 (e) piroxicam with 4NZ2 (f) piroxicam with 2AYR and (g) isoxicam with 3DY9 (h) isoxicam with 4NZ2 (i) isoxicam with 2AYR at the active sites of proteins.

Table 4

The top ten conformation of the complex candidate of ligands.

No.Global
Attractive
Repulsive
Atomic Contact
EnergyVdwVdwEnergy
4.1: Tenoxicam with 3DY9
1-24.54-10.314.74-10.59
2-23.13-9.643.26-9.97
3-20.96-8.233.68-9.86
4-19.95-8.813.95-8.85
5-19.00-9.764.36-7.27
6-18.42-8.523.30-6.46
7-18.03-10.124.77-6.69
8-17.80-8.151.05-5.16
9-17.65-6.411.11-6.73
10-16.05-11.046.24-4.37
4.2: Tenoxicam with 4NZ2
1-34.66-16.3212.43-13.55
2-31.94-17.609.76-8.63
3-31.87-15.123.04-81.0
4-31.68-14.014.05-10.74
5-31.34-15.297.15-10.20
6-31.01-13.512.10-8.87
7-30.53-13.989.73-12.44
8-29.49-15.724.58-6.27
9-29.32-12.552.09-9.18
10-28.73-18.445.89-6.08
4.3: Tenoxicam with 2AYR
1-41.31-17.014.57-14.33
2-40.33-15.823.69-12.34
3-37.62-15.705.96-12.74
4-37.42-15.774.36-13.93
5-36.79-14.474.89-12.86
6-36.31-14.687.37-14.24
7-35.81-16.056.72-12.25
8-33.94-13.083.54-11.40
9-33.89-14.922.07-10.81
10-33.11-16.887.67-11.98
4.4: Piroxicam with 3DY9
1-21.21-9.131.14-6.21
2-19.67-9.401.72-6.40
3-19.37-8.702.61-8.16
4-19.32-9.501.49-5.22
5-19.26-9.604.33-7.93
6-18.28-8.854.22-7.68
7-16.16-6.832.99-6.25
8-16.08-11.303.95-3.14
9-15.74-11.8610.39-5.40
10-14.54-7.953.79-6.54
4.5: Piroxicam with 4NZ2
1-31.03-15.283.95-7.96
2-30.98-12.001.99-9.53
3-30.62-15.972.28-6.32
4-30.06-19.114.45-5.50
5-30.05-16.218.99-10.29
6-29.95-16.894.80-5.55
7-29.60-13.912.61-8.22
8-29.33-14.445.50-9.38
9-28.70-16.153.84-5.78
10-28.66-15.184.96-7.65
4.6: Piroxicam with 2AYR
1-37.85-17.335.90-12.41
2-36.08-16.484.57-10.83
3-35.96-17.164.34-11.19
4-34.04-14.504.95-11.94
5-33.99-15.735.94-12.53
6-33.99-15.116.47-11.55
7-33.51-3.653.54-11.09
8-33.12-15.102.21-7.97
9-31.94-14.231.24-7.53
10-31.02-12.451.87-10.00
4.7: Isoxicam with 3DY9
1-26.00-11.533.63-10.59
2-25.72-13.303.88-8.13
3-23.43-8.481.41-8.64
4-19.41-11.685.27-5.59
5-19.35-9.102.36-7.89
6-19.18-10.493.90-6.91
7-19.07-8.183.38-7.26
8-18.81-8.404.97-8.39
9-18.60-12.287.80-5.68
10-18.36-7.930.54-7.12
4.8: Isoxicam with 4NZ2
1-37.12-16.162.35-10.90
2-34.72-13.372.18-12.16
3-33.12-12.590.90-9.56
4-32.08-15.245.98-9.06
5-31.53-15.554.47-8.39
6-29.81-16.072.44-5.55
7-29.54-13.010.78-8.32
8-28.60-16.098.45-8.67
9-27.16-14.205.24-8.46
10-27.05-12.262.32-8.50
4.9: Isoxicam with 2AYR
1-42.31-19.705.02-12.99
2-38.46-16.622.34-9.76
3-34.63-14.962.06-9.48
4-34.52-15.483.75-10.61
5-33.93-14.411.86-9.98
6-33.62-15.273.42-11.22
7-30.98-14.967.86-9.62
8-30.94-12.875.08-12.59
9-29.64-11.613.41-10.35
10-29.61-15.414.42-9.28
The interactive plot of docked ligands (a) n class="Chemical">tenoxicam with 3DY9 (b) class="Chemical">pan class="Chemical">tenoxicam with 4NZ2 (c) tenoxicam with 2AYR (d) piroxicam with 3DY9 (e) piroxicam with 4NZ2 (f) piroxicam with 2AYR and (g) isoxicam with 3DY9 (h) isoxicam with 4NZ2 (i) isoxicam with 2AYR. The docked ligands (a) n class="Chemical">tenoxicam with 3DY9 (b) class="Chemical">pan class="Chemical">tenoxicam with 4NZ2 (c) tenoxicam with 2AYR (d) piroxicam with 3DY9 (e) piroxicam with 4NZ2 (f) piroxicam with 2AYR and (g) isoxicam with 3DY9 (h) isoxicam with 4NZ2 (i) isoxicam with 2AYR at the active sites of proteins. The top ten conformation of the complex candidate of ligands.

Conclusion

The spectroscopic analysis of n class="Chemical">tenoxicam, class="Chemical">pan class="Chemical">piroxicam and isoxicam are reported. The theoretical normal modes of vibrations based on DFT theory has been investigated and compared with the experimental values. NBO analysis was carried out on the molecule to find the interactions and found that these compounds are highly stable due to hyperconjugative interactions. Simulated electronic spectra show that there is an intense peak in red shift region due to pi to anti-bonding π-electron transition and a weak peak due to lone pair to anti-bonding orbital transition. The lower value of HOMO and LUMO energy gap describes the stability and biological activity of the tenoxicam, piroxicam and isoxicam compounds. Reactive sites were obtained from MEP, which indicates that there are enough sites for nucleophilic and electrophilic interaction in the molecules, which is very important to show biological activities. Finally the molecular docking shows the ligands have good pharmacological properties with the proteins. From atomic contact energy and global energy values more stable complex are identified.

Declarations

Author contribution statement

Y. Shyma Mary, Y. Sheena Mary, K.S. Resmi, Renjith Thomas: Conceived and designed the analysis; Analyzed and interpreted the data; Wrote the paper.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.
  13 in total

1.  PASS: prediction of activity spectra for biologically active substances.

Authors:  A Lagunin; A Stepanchikova; D Filimonov; V Poroikov
Journal:  Bioinformatics       Date:  2000-08       Impact factor: 6.937

2.  A protein-protein docking benchmark.

Authors:  Rong Chen; Julian Mintseris; Joël Janin; Zhiping Weng
Journal:  Proteins       Date:  2003-07-01

3.  Single crystal XRD, DFT investigations and molecular docking study of 2- ((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino)naphthalene-1,4-dione as a potential anti- cancer lead molecule.

Authors:  Kavitha Rani P R; Y Sheena Mary; Annette Fernandez; Anu Priya S; Y Shyma Mary; Renjith Thomas
Journal:  Comput Biol Chem       Date:  2018-11-30       Impact factor: 2.877

4.  Molecular structure, FT-IR, NBO, HOMO and LUMO, MEP and first order hyperpolarizability of (2E)-1-(2,4-Dichlorophenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one by HF and density functional methods.

Authors:  Y Sheena Mary; C Yohannan Panicker; P L Anto; M Sapnakumari; B Narayana; B K Sarojini
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2014-07-08       Impact factor: 4.098

5.  Theoretical investigations on the molecular structure, vibrational spectral, HOMO-LUMO and NBO analysis of 9-[3-(Dimethylamino)propyl]-2-trifluoro-methyl-9H-thioxanthen-9-ol.

Authors:  Y Sheena Mary; C Yohannan Panicker; T S Yamuna; M S Siddegowda; H S Yathirajan; Abdulaziz A Al-Saadi; Christian Van Alsenoy
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2014-05-16       Impact factor: 4.098

6.  FT-IR, molecular structure, first order hyperpolarizability, HOMO and LUMO analysis, MEP and NBO analysis of 2-(4-chlorophenyl)-2-oxoethyl 3-nitrobenzoate.

Authors:  C S Chidan Kumar; C Yohannan Panicker; Hoong-Kun Fun; Y Sheena Mary; B Harikumar; S Chandraju; Ching Kheng Quah; Chin Wei Ooi
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2014-02-12       Impact factor: 4.098

7.  Molecular structure, FT-IR, vibrational assignments, HOMO-LUMO analysis and molecular docking study of 1-[5-(4-Bromophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]ethanone.

Authors:  Y Sheena Mary; C Yohannan Panicker; M Sapnakumari; B Narayana; B K Sarojini; Abdulaziz A Al-Saadi; Christian Van Alsenoy; Javeed Ahmad War; H K Fun
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2014-09-28       Impact factor: 4.098

8.  First-principles prediction of the pK(a)s of anti-inflammatory oxicams.

Authors:  Junming Ho; Michelle L Coote; Marco Franco-Pérez; Rodolfo Gómez-Balderas
Journal:  J Phys Chem A       Date:  2010-11-11       Impact factor: 2.781

9.  Synthesis, spectroscopic and DFT structural characterization of two novel ruthenium(III) oxicam complexes. In vivo evaluation of anti-inflammatory and gastric damaging activities.

Authors:  Gabriella Tamasi; Caterina Bernini; Gianfranco Corbini; Natalie F Owens; Luigi Messori; Federica Scaletti; Lara Massai; Pietro Lo Giudice; Renzo Cini
Journal:  J Inorg Biochem       Date:  2014-01-25       Impact factor: 4.155

10.  Photophysical studies of oxicam group of NSAIDs: piroxicam, meloxicam and tenoxicam.

Authors:  Rona Banerjee; Hirak Chakraborty; Munna Sarkar
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2003-04       Impact factor: 4.098

View more
  3 in total

1.  Adsorption of adipic acid in Al/B-N/P nanocages: DFT investigations.

Authors:  Jamelah S Al-Otaibi; Y Sheena Mary; Y Shyma Mary; Goncagül Serdaroglu
Journal:  J Mol Model       Date:  2021-03-25       Impact factor: 1.810

2.  Detailed molecular structure (XRD), conformational search, spectroscopic characterization (IR, Raman, UV, fluorescence), quantum mechanical properties and bioactivity prediction of a pyrrole analogue.

Authors:  Katta Eswar Srikanth; A Veeraiah; T Pooventhiran; Renjith Thomas; K Anand Solomon; Ch J Soma Raju; J Naveena Lavanya Latha
Journal:  Heliyon       Date:  2020-06-03

3.  Drug dual-release matrix proprieties and the correlations with nanostructure aggregation kinetics for siloxane-polyether/hydrogel nanocomposites.

Authors:  Mac-Kedson Medeiros Salviano Santos; Marcelo Henrique Sousa; Juliano Alexandre Chaker
Journal:  RSC Adv       Date:  2021-01-19       Impact factor: 3.361

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.